WAY100635 prevents the changes induced by fluoxetine upon the 5-HT1A receptor functionality

Neuropharmacology

Volumn 55, Issue 8, 2008, Pages 1391-1396

  Castro, Elena ^a,b   Díaz, Alvaro ^a,b   Rodriguez Gaztelumendi, Antonio ^a,b   del Olmo, Elena ^a   Pazos, Angel ^a,b  

^a UNIVERSITY OF CANTABRIA   (Spain)

^b University of Cantabria   (Spain)

Author keywords

5 HT1A receptors; 35S GTP S autoradiography; Fluoxetine; G proteins and electrophysiology; WAY100635

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; FLUOXETINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; DRUG EFFECT; DRUG RECEPTOR BINDING; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; WISTAR RAT;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; AUTORADIOGRAPHY; BRAIN; DRUG INTERACTIONS; FLUOXETINE; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); MALE; PIPERAZINES; PROTEIN BINDING; PYRIDINES; RADIOISOTOPES; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 56249093772     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2008.08.038     Document Type: Article

References (47)

1. Adell A., Castro E., Celada P., Bortolozzi A., Pazos A., and Artigas F. Strategies for producing faster acting antidepressants. Drug Discov. Today 10 (2005) 578-585
2. Aghajanian G.K., Foot W.E., and Sheard M.H. Action of psychotogenic drugs on single midbrain raphe neurons. J. Pharmacol. Exp. Ther. 171 (1970) 178-187
3. Artigas F., Adell A., and Celada P. Pindolol augmentation of antidepressant response. Curr. Drug Targets 7 (2006) 139-147
4. Artigas F., Perez V., and Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry 51 (1994) 248-251
5. Béïque J., de Montigny C., Blier P., and Debonnel G. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. in vivo electrophysiological studies in the rat. Neuropharmacology 39 (2000) 1800-1812
6. Blier P., and de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15 (1994) 220-226
7. Bristow L.J., O'Connor D., Watts R., Duxon M.S., and Hutson P.H. Evidence for accelerated desensitisation of 5-HT(2C) receptors following combined treatment with fluoxetine and the 5-HT(1A) receptor antagonist, WAY 100,635, in the rat. Neuropharmacology 39 (2000) 1222-1236
8. 1A receptor antagonist co-administration. J. Neurochem. 85 (2003) 1480-1487
9. 1A receptors in rat brain. Neuropharmacology 44 (2003) 93-101
10. Chaput Y., de Montigny C., and Blier P. Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Naunyn Schmiedeberg's Arch. Pharmacol. 333 (1986) 342-348
11. B receptor function in dorsal raphé neurons upon chronic fluoxetine treatment of socially stressed rats. J. Neurophysiol. 98 (2007) 1-2
12. Cryan J.F., Valentino R.J., and Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci. Biobehav. Rev. 29 (2005) 547-569
13. Dawson L.A., Nguyen H.Q., Smith D.I., and Schechter L.E. Effects of chronic fluoxetine treatment in the presence and absence of (±)pindolol: a microdialysis study. Br. J. Pharmacol. 130 (2000) 797-804
14. Dawson L.A., Nguyen H.Q., Smith D.L., and Schechter L.E. Effect of chronic fluoxetine and WAY-100635 treatment on serotonergic neurotransmission in the frontal cortex. J. Psychopharmacol. 16 (2002) 145-152
15. Fernández-Pérez S., Pache D.M., and Sewell R.D. Co-administration of fluoxetine and WAY100635 improves short-term memory function. Eur. J. Pharmacol. 522 (2005) 78-83
16. 1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. Br. J. Pharmacol. 115 (1995) 1064-1070
17. Gartside S.E., Clifford E.M., Cowen P.J., and Sharp T. Effects of (-)-tertatolol, (-)-penbutolol and (+/-)-pindolol in combination with paroxetine on presynaptic 5-HT function: an in vivo microdialysis and electrophysiological study. Br. J. Pharmacol. 127 (1999) 145-152
18. Grignaschi G., Invernizzi R.W., Fanelli E., Fracasso C., Caccia S., and Samanin R. Citalopram-induced hypophagia is enhanced by blockade of 5-HT(1A) receptors: role of 5-HT(2C) receptors. Br. J. Pharmacol. 124 (1998) 1781-1787
19. 1A receptors. J. Neurosci. 18 (1998) 10150-10156
20. Harasawa T., Ago Y., Itoh S., Baba A., and Matsuda T. Role of serotonin type 1A receptors in fluvoxamine-induced inhibition of marble-burying behavior in mice. Behav. Pharmacol. 17 (2006) 637-640
21. 1A receptor-G protein interactions in brain following chronic antidepressant administration. Neuropsychopharmacology 26 (2002) 565-573
22. 1A autoreceptors by a low chronic fluoxetine dose. Effect of the concurrent administration of WAY-100635. Neuropsychopharmacology 24 (2001) 11-20
23. 1A (auto)receptor blocker versus that of the 5-HT reuptake inhibitor. Neuropharmacology 36 (1997) 461-465
24. 1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur. J. Pharmacol. 510 (2005) 49-57
25. B receptor-mediated inhibition of serotonergic neurons. Eur. J. Pharmacol. 143 (1987) 195-204
26. 1A receptors. Eur. J. Pharmacol. 260 (1994) 243-246
27. 1A receptors in the effects of acute chronic fluoxetine on extracellular serotonin in the frontal cortex. Pharmacol. Biochem. Behav. 54 (1996) 143-147
28. 1B receptors and 5-HT transporter in rats treated chronically with fluoxetine. Neuropharmacology 39 (2000) 110-122
29. 1A agonist. J. Pharmacol. Exp. Ther. 279 (1996) 1035-1042
30. Mannoury la Cour C., El Mestikawy S., Hanoun N., Hamon M., and Lanfumey L. Regional differences in the coupling of 5-hydroxytryptamine-1A receptors to G proteins in the rat brain. Mol. Pharmacol. 70 (2006) 1013-1021
31. Millan M.J. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol. Ther. 110 (2006) 135-370
32. 1B autoreceptors: regional differences and effects of WAY-100635. Eur. J. Pharmacol. 486 (2004) 25-30
33. 1A) receptors. Neuropsychopharmacology 18 (1998) 395-398
34. Pazos A., and Palacios J.M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res. 346 (1985) 205-230
35. 1A autoreceptor occupancy by pindolol is attenuated in depressed patients: effect of treatment or an endophenotype of depression?. Neuropsychopharmacology 29 (2004) 1688-1698
36. 1A autoreceptors on the plasma membrane of nucleus raphe dorsalis neurons in rats chronically treated with fluoxetine. Neuroscience 151 (2008) 692-700
37. 1A receptors: in vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology 15 (1996) 349-360
38. 1A receptor antagonists in the dorsal raphe pathway: role of somatodendritic autoreceptors. J. Neurochem. 68 (1997) 2593-2603
39. Rojas-Corrales M.O., Ortega-Alvaro A., Gibert-Rahola J., Roca-Vinardell A., and Micó J.A. Pindolol, a beta-adrenoceptor blocker/5-hydroxytryptamine(1A/1B) antagonist, enhances the analgesic effect of tramadol. Pain 88 (2000) 119-124
40. 14C]WAY-100635. Effects of depression and antidepressant treatment. Arch. Gen. Psychiatry 57 (2000) 174-180
41. Segrave R., and Nathan P.J. Pindolol augmentation of selective serotonin reuptake inhibitors, accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression. Hum. Psychopharmacol. 20 (2005) 163-174
42. 1A receptors in hypothalamus. J. Pharmacol. Exp. Ther. 294 (2000) 296-301
43. 35S]thio]-triphosphate binding. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 7242-7246
44. 1B agonists. Synapse 1 (1987) 3-9
45. 1A receptor antagonism/SSRI activities. Part 2. Bioorg. Med. Chem. Lett. 13 (2003) 2393-2397
46. 1A receptor antagonists. Eur. J. Pharmacol. 18 (1998) 179-184
47. Vicentic A., Li Q., Battaglia G., and Van de Kar L.D. WAY-100635 inhibits 8-OH-DPAT-stimulated oxytocin, ACTH and corticosterone, but not prolactin secretion. Eur. J. Pharmacol. 346 (1998) 261-266